Biogen And Denali Discontinue BIIB122 Development In Idiopathic Parkinson's Disease After Phase 2b LUMA Trial Misses Primary And Secondary Endpoints
Denali Therapeutics Inc DNLI
$18.65
▼ -3.37%
($-0.65)
Open
$18.53
Prev Close
$19.30
Day Range
$18.18 – $19.06
52W Range
$12.58 – $23.77
Market Cap
$2.96B
Beta
0.96
EPS (TTM)
$-2.97
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-12-08 |
| Shares Out. | 158,710,000 |
| Website | denalitherapeutics.com ↗ |
| Phone | 13026587581 |
Denali Therapeutics Inc is a publicly traded company under the ticker symbol DNLI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
25 analysts (2026-05-01)
📰 Latest News for DNLI
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $40
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Transcript : Denali Therapeutics Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03
BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target